

\*E-Filed 04/28/2010\*

1

2

3

4

5

6

7

8

IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF CALIFORNIA  
SAN JOSE DIVISION

9

10

11

AQUA-LUNG AMERICA, INC., a  
Delaware Corporation,

No. C 07-02346 RS

13

14

Plaintiff,

**ORDER GRANTING IN PART AND  
DENYING IN PART SUMMARY  
JUDGMENT**

15

v.

16

AMERICAN UNDERWATER  
PRODUCTS, INC., d/b/a OCEANIC, a  
California Corporation; and TWO FORTY  
DEUCE CORPORATION, a Colorado  
Corporation,

19

Defendants.

20

21

22

I. INTRODUCTION

23

24

25

26

27

28

This case arises out of a series of scuba equipment patents. At the heart of the dispute are three patents held by defendant Two Forty Deuce (“TFD”) and exclusively licensed to defendant American Underwater Products, d/b/a Oceanic (“AUP”): U.S. Patent No. 6,601,609, issued August 5, 2003 (the “609 Patent”); U.S. Patent No. 6,901,958, issued June 7, 2005 (the “958 Patent”); and U.S. Patent No. 7,185,674, issued March 6, 2007 (the “674 Patent”). Plaintiff Aqua-Lung America, Inc. (“Aqua-Lung”) filed a complaint for declaratory judgment of patent invalidity and non-

No. C 07-02346 RS  
ORDER



1 connected to the hose/regulator assembly and close whenever the scuba tank is detached. A gas-  
2 pressure activated valve, by contrast, is designed to close when the air pressure on the downstream  
3 side of the valve equalizes with the air pressure on the upstream side of the valve. In practice, this  
4 means the valve opens and closes every time the diver inhales and draws air from the pressurized  
5 scuba tank. Aqua-Lung's valve is mechanically activated.

6 Aqua-Lung filed a complaint in April 2007 and an amended complaint in July 2007. The  
7 amended complaint sought a declaratory judgment that Aqua-Lung's valve does not infringe the  
8 three patents-in-suit. It also sought a declaratory judgment of invalidity as to all three Oceanic  
9 patents. Oceanic counter-claimed for infringement, for misappropriation of trade secrets in violation  
10 of Cal. Civil Code § 3426, and for fraud/misrepresentation. The Court issued its claim construction  
11 order in February 2009. Aqua-Lung seeks summary judgment rejecting Oceanic's fraud and trade  
12 secret misappropriation claims and invalidating the patents-in-suit. The parties have also brought  
13 cross-motions seeking to have infringement resolved one way or another, as a matter of law. The  
14 parties presented argument on these motions on March 24, 2010.

### 15 III. LEGAL STANDARDS

#### 16 A. Summary Judgment Generally

17 A motion for summary judgment should be granted if there is no genuine issue of material  
18 fact and the moving party is entitled to judgment as a matter of law. Fed. R. Civ. P. 56(c); *Anderson*  
19 *v. Liberty Lobby, Inc.*, 477 U.S. 242, 247-48 (1986). The purpose of summary judgment "is to  
20 isolate and dispose of factually unsupported claims or defenses." *Celotex v. Catrett*, 477 U.S. 317,  
21 323-24 (1986). The moving party bears the initial burden of informing the Court of the basis for the  
22 motion and identifying those portions of the pleadings, depositions, answers to interrogatories,  
23 admissions, or affidavits which demonstrate the absence of a triable issue of material fact. *Id.* at  
24 323.

25 If the moving party meets its initial burden, it then shifts to the non-moving party to present  
26 specific facts showing that there is a genuine issue of material fact for trial. Fed. R. Civ. P. 56(e);  
27 *Celotex*, 477 U.S. at 324. The evidence and all reasonable inferences therefrom must be viewed in  
28

1 the light most favorable to the non-moving party. *T.W. Elec. Serv., Inc. v. Pac. Elec. Contractors*  
2 *Ass'n*, 809 F.2d 626, 630-31 (9th Cir. 1987). The opposing party “must do more than simply show  
3 that there is some metaphysical doubt as to the material facts.” *Matsushita Elec. Indus. Co. v.*  
4 *Zenith Radio*, 475 U.S. 574, 588 (1986). Summary judgment is not appropriate if the nonmoving  
5 party presents evidence from which a reasonable jury could resolve the disputed issue of material  
6 fact in his or her favor. *Anderson*, 477 U.S. at 248; *Barlow v. Ground*, 943 F.2d 1132, 1136 (9th  
7 Cir. 1991). Nonetheless, “[w]here the record taken as a whole could not lead a rational trier of fact  
8 to find for the nonmoving party, there is no genuine issue for trial.” *Matsushita*, 475 U.S. at 587  
9 (internal quotation marks omitted).

10 B. Summary Judgment Standards Regarding Patent Infringement and Invalidity

11 With regard to the parties’ cross-motions on infringement, summary judgment is  
12 appropriate: 1) where “only one conclusion as to infringement could be reached by a reasonable  
13 jury;” or 2) “when the patent owner's proof is deficient in meeting an essential part of the legal  
14 standard for infringement, because such failure will render all other facts immaterial.” *TechSearch,*  
15 *L.L.C. v. Intel Corp.*, 286 F.3d 1360, 1369 (Fed. Cir. 2002). Patent infringement analysis involves  
16 two steps: 1) claim construction; and 2) application of the properly construed claims to the accused  
17 device or method. *See Markman v. Westview Instruments, Inc.*, 52 F.3d 967, 976 (Fed. Cir. 1995)  
18 (en banc). The first step is a question of law. *Id.* at 979. In the instant litigation, the Court  
19 completed this step with the claim construction order. The parties, through their cross-motions,  
20 suggest the time has now arrived for the second step of the infringement analysis.

21 To prove infringement, a patent holder must show that the accused device or method meets  
22 each claim limitation, either literally or under the doctrine of equivalents. *See Deering Precision*  
23 *Instruments, L.L.C. v. Vector Distrib. Sys., Inc.*, 347 F.3d 1314, 1324 (Fed. Cir. 2003). Here,  
24 Oceanic’s infringement arguments center on the “literal” prong. A literal infringement analysis  
25 takes the claims that the Court has previously construed and compares them to the accused device.  
26 *See Markman*, 52 F.3d at 976. “To establish literal infringement, all of the elements of the claim, as  
27 correctly construed, must be present in the accused system.” *TechSearch, L.L.C.*, 286 F.3d at 1371.

28

No. C 07-02346 RS  
ORDER

1 “Any deviation from the claim precludes such a finding.” *Telemac Cellular Corp. v. Topp Telecom,*  
2 *Inc.*, 247 F.3d 1316, 1330 (Fed. Cir. 2001). The patent holder bears the burden of proving that each  
3 accused product “includes every limitation of [an asserted] claim or an equivalent of each  
4 limitation.” *Dolly, Inc. v. Spalding & Evenflo Cos.*, 16 F.3d 394, 397 (Fed. Cir. 1994).

5 Infringement is a question of fact. *Frank’s Casing Crew & Rental Tools, Inc. v.*  
6 *Weatherford Int’l, Inc.*, 389 F.3d 1370, 1376 (Fed. Cir. 2004); *see also Bai v. L&L Wings, Inc.*, 160  
7 F.3d 1350, 1353 (Fed. Cir. 1998) (holding that the second step of the infringement analysis is a  
8 factual question). The court can resolve the issue on summary judgment only if “no reasonable jury  
9 could find that every limitation recited in the properly construed claim either is or is not found in the  
10 accused device.” *Frank’s Casing Crew*, 389 F.3d at 1376. That said, the absence from the accused  
11 product of one limitation in the claim means that, as a matter of law, there is no literal infringement  
12 of that claim. *Id.*

13 With respect to invalidity, summary judgment is as appropriate in a patent case as it is in any  
14 other case. *C.R. Bard Inc. v. Advanced Cardiovascular Sys.*, 911 F.2d 670, 672 (Fed. Cir.1990). A  
15 patent is presumed valid. 35 U.S.C. § 282. The burden is on the party challenging the patent to  
16 show, by clear and convincing evidence, that the patent is invalid. *See, e.g., Hybritech Inc. v.*  
17 *Monoclonal Antibodies, Inc.*, 802 F.2d 1367 (Fed. Cir. 1986); *see also Invitrogen Corp. v. Clontech*  
18 *Labs., Inc.*, 429 F.3d 1052, 1063 (Fed. Cir. 2005) (requiring the party asserting invalidity to prove  
19 by clear and convincing evidence that the invention was not abandoned, suppressed, or concealed  
20 under § 102(g)). Because this standard must be employed at the summary judgment stage just as it  
21 would be used at trial, Aqua-Lung has the burden of showing that there is an undisputed record from  
22 which a finder of fact would find by clear and convincing evidence that the three patents-in-suit are  
23 invalid. *Eli Lilly & Co. v. Barr Lab., Inc.*, 251 F.3d 955, 962 (Fed. Cir. 2001).

#### 24 IV. ANALYSIS

##### 25 A. Infringement

26 Aqua-Lung moves for summary judgment on its claim of non-infringement of the patents-in-  
27 suit, and Oceanic moves for summary judgment on its corresponding infringement counter-claim.

1 These motions pose similar issues and are effectively cross-motions for summary judgment. As a  
2 result, they will be addressed together.

3 1. The '674 Patent<sup>1</sup>

4 a. Location of Pressure Responsive Element and Spring

5 Claim 1 of the '674 Patent discusses a device called the pressure responsive element<sup>2</sup>  
6 (“PRE”), along with an accompanying spring that is “configured to bias” the PRE. '674 Patent,  
7 col.26 l.46, 49. The first set of arguments in the cross-motions concerns the position of this  
8 PRE/spring assembly within the disputed valve design. The second and third limitations of Claim 1  
9 of the '674 Patent describe a PRE “located *within the bore*” and “a spring located *within the bore*.”  
10 *Id.* (emphasis added). Aqua-Lung contends that Claim 1 of the '674 patent protects only devices  
11 whose PREs and accompanying springs are positioned within the filter assembly’s “bore,” and that  
12 the accused products’ PREs and springs are outside such a bore. Oceanic disagrees, contending that  
13 the casing in which the PREs and springs are housed qualifies as a “bore,” and therefore the accused  
14 devices cannot be differentiated on this basis.

15 During claim construction, the Court defined a “bore” as “a cylindrical hole or passage.”  
16 Aqua-Lung contends the PRE and spring in the accused devices occupy a space that is not  
17 cylindrical, but annular—i.e., ring-shaped (like a doughnut). Oceanic protests that the term  
18 “cylindrical” refers to *any* round hole or passage, regardless of whether the passage has a hollowed-  
19 out center like an annulus; and thus, the fact that Aqua-Lung’s PRE and spring are located in an  
20 annular space does not preclude a finding on summary judgment that this claim was infringed.

21  
22  
23 <sup>1</sup> After initially suggesting that it is seeking summary judgment on the Kronos, Legend, and Titan  
24 lines of regulators, Oceanic noted that the Kronos line uses “a disc-shaped filter rather than a cone-  
25 shaped one” like the Titan and Legend lines. Defendants’ Motion for Summary Judgment of Patent  
26 Infringement at 3. Thus, it conceded the Kronos line does not infringe on the '674 Patent. *Id.* at 4-  
27 14. Therefore, summary judgment will be granted in favor of Aqua-Lung with respect to the issue  
28 of whether the Kronos line infringes on the '674 Patent.

<sup>2</sup> During claim construction, the Court defined a PRE as “an element of a device which can move  
from a first position where it prevents fluid flow into the device, to a second position, where it  
allows fluid flow into the device.” Order Construing Claims at 24.

1           These arguments turn on the question of whether the term “bore” should be read to  
2 encompass annular spaces. The claim construction order’s discussion of the term is instructive in  
3 this regard. It states that “a review of the embodiments [of the patents-in-suit] accompanying the  
4 specification reveals that a ‘bore’ is portrayed as a *circular* opening or hole in the housing . . . Two-  
5 Forty’s proposed definition [of a ‘bore’ as ‘a hole or passage’], however, lacks the ‘cylindrical’  
6 qualifying element that Aqua-Lung proposed and is present in the embodiments. At the hearing,  
7 both sides agreed that the term ‘bore’ does bring in this cylindrical concept.” Order Construing  
8 Claims at 8; *see also* Transcript of *Markman* Hearing at 121 (when the Court inquired whether there  
9 was any difference between a “hole” and “an internal passageway that is cylindrical,” defense  
10 counsel conceded there was no difference “that [he] could think of currently”). Thus, the Court’s  
11 primary concern at the claim construction stage was the *circularity* of the bore, not the *hollowness*.  
12 For this reason, Oceanic’s interpretation of the definition of “bore”—essentially any round hole or  
13 tube, whether hollow or solid—is faithful to the Court’s original intent in the claim construction  
14 order.

15           For this reason, the PREs and springs in the accused devices, which are positioned in an  
16 annular space inside the valve in Aqua-Lung’s designs, can fairly be said to be located “within a  
17 bore.” In the absence of any disputed issues of fact on this issue, with respect to the location of the  
18 PRE and spring in claim 1 of the ’674 Patent, the accused devices do not meaningfully differ from  
19 the device claimed in the patent.

20           b.       Retainer Device

21           The parties next disagree on whether the accused devices contain a “retainer device.” This  
22 term is present in the fifth limitation of Claim 1, which describes “a retainer device for removably  
23 securing the filter.”

24           Aqua-Lung argues that the accused devices’ O-ring does not fall within the concept of  
25 “retainer device,” because it cannot hold the filter in place against a blast of pressurized gas (a fact  
26 which Aqua-Lung’s expert claims to have demonstrated). Therefore, Aqua-Lung contends, its O-  
27 ring does not “secure” the filter. Oceanic counters that, even if the O-ring does not secure the filter  
28

1 against a blast of air, it nonetheless fixes the filter strongly enough in place to prevent it from falling  
2 out whenever someone picks up the device. This, Oceanic claims, is all the patents mean by  
3 “secure.”

4 This question—effectively, how secure is “secure”—was not addressed directly during the  
5 claim construction phase. At that time, the Court defined “retainer device” as “a mechanism  
6 configured removably to secure the filter and other parts within the passageway.” Order Construing  
7 Claims at 13. The language of the claims, which the order quotes throughout and explicitly bases  
8 itself upon, reads “configured *to removably secure*.” The original patent phrase “for removably  
9 securing the filter” was unquestionably the basis of the claim construction order; and this phrase  
10 unambiguously denotes an ability to take the filter on and off easily. Thus Oceanic’s argument—  
11 effectively that “to secure” does not mean “to fix immovably against all imaginable forces”—is  
12 more persuasive here.

13 Aqua-Lung also attempts to distinguish its accused devices on the basis of the Court’s phrase  
14 “the filter and other parts.” According to Aqua-Lung, the O-ring secures the filter but *not* any other  
15 parts, so the O-ring does not fall within the definition of “retainer device.” Oceanic contends the  
16 “and” is disjunctive (i.e. it means “and/or”); so if the mechanism secures the filter *and/or* any other  
17 parts, it falls within the definition of retainer device. Aqua-Lung’s proposed interpretation is  
18 nonsensical—even Oceanic’s own embodiments would be unlikely to satisfy the term “retainer  
19 device” if they were required to secure the filter *as well as* “other parts.” Interpreting “and”  
20 disjunctively is more faithful to the meaning of the claim language, as well as the intent of the claim  
21 construction order. Again, absent a genuine disputed factual question, the accused devices cannot  
22 be distinguished on the basis that they lack a retainer device, as set forth in Claim 5.

23 c. “Fluid Must Pass”

24 The seventh limitation of Claim 1 and the ninth limitation of Claim 13 in the ’674 Patent are  
25 very similar. The former states: “wherein the filter is sized and shaped to block the exit opening *so*  
26 *that fluid must pass through the filter* to pass through the exit opening.” ’674 Patent, col. 26 l.59-61  
27 (emphasis added). The latter states: “wherein the filter is located *so that fluid must pass through the*

1 *filter* to pass through the gas outlet opening.” *Id.*, col.28 l.1-2 (emphasis added). Oceanic contends  
2 that Aqua-Lung’s filter is designed to prevent any fluid (generally gas) from entering the regulator  
3 without passing through the filter, just as Claims 1 and 13 describe. Aqua-Lung counters that even  
4 if its filter is blocked, air will still get through to the regulator, thus indicating that the accused  
5 products are not designed so that fluid *must* pass—only so that it *may* pass.

6 When the phrase “fluid must pass” is read in the context of the remaining language in the  
7 two limitations at issue, Oceanic’s interpretation is compelling. Both claims utilize the phrase “so  
8 that,” which is a final coordinating conjunction. Such conjunctions denote inferences or  
9 consequences. The second clause gives a reason for the first clause’s statement, or it shows what  
10 has been or ought to be done in view of the first clause’s expression. Here, “so that fluid must pass”  
11 *gives a reason* for why “the filter is sized and shaped to block the exit opening,” in the words of  
12 Claim 1; and it *gives a reason* for where “the filter is located,” in the words of Claim 13. That is, in  
13 determining whether a particular device falls within the claim language, the relevant inquiry is the  
14 *intent* behind the filter’s positioning.

15 Aqua-Lung does not deny that its design is *intended* to direct air through the filter on its way  
16 out the exit opening of the valve. Aqua-Lung’s own expert admitted that, in normal use, gas would  
17 travel through the top of the valve and “some of it would probably come through the filter,” and  
18 that, based on his experience as a mechanical engineer, “I’d expect that you’d *want* to have the air  
19 go through the filter.” Cagan Deposition at 4-5, attached as Exh. 4 to Kauth Declaration (emphasis  
20 added). Even a layman can understand that a filter located in an air passageway is almost certainly  
21 in place to filter air; and in any event, Aqua-Lung has offered no other reason for the filter’s  
22 presence in the accused devices. Rather, in effect, Aqua-Lung appears to be claiming that its design  
23 does not infringe because the filter does not work as well as it should. As discussed above,  
24 however, the claims make clear that what matters is how the filter is *intended* to work.

25 In light of these considerations, the accused devices cannot reasonably be said to differ  
26 meaningfully from the designs described in the seventh limitation of Claim 1 and the ninth  
27 limitation of Claim 13. Rather, they embody these limitations.

1 d. “Removable through the exit opening”

2 The tenth limitation of Claim 1 of the '674 Patent states: “wherein the retainer device is  
3 configured such that the filter is removable through the exit opening.” '674 Patent, col. 26 l.62-63.  
4 The twelfth limitation of Claim 13 similarly states: “wherein the retainer device is configured such  
5 that the filter is removable through the gas outlet opening.” *Id.*, col. 28 l.4-5. Aqua-Lung does not  
6 deny that the filter in the accused devices is removed through the exit opening; but nonetheless it  
7 asks the Court to interpret the claims as requiring the retainer device to be configured “such that the  
8 filter can be removed through the exit opening only after the retaining device has first been  
9 removed.” It then argues that its own models differ because they allow the filter to be removed  
10 *simultaneously* with the retainer device. Aqua-Lung, however, has offered no persuasive argument  
11 as to why the limitation it proposes should be read into the claim language. It is undisputed that the  
12 filter on Aqua-Lung’s device comes out through the exit opening (and/or the gas outlet opening) and  
13 nowhere else. Aqua-Lung’s attempt to distinguish the accused devices on this ground is therefore  
14 unavailing.

15 e. “Housing Defining an Internal Passageway”

16 The final limitation contested by the parties in the '674 Patent is the fourth limitation of  
17 Claim 13, which states that the fluid flow control valve in the design is comprised of, among other  
18 things, “a housing defining an internal passageway, where the passageway has a gas inlet opening  
19 near an upstream end of said housing and a gas outlet opening near a downstream end of said  
20 housing and spaced from the gas inlet opening.” '674 Patent, col.27 l.31-35.

21 The Court has defined “passageway” as “a conduit formed in the housing that allows gas to  
22 pass through it.” Order Construing Claims at 6. There can be little question that the fixed central  
23 post, through which the air flows in the accused devices, matches this description. Aqua-Lung  
24 repeats its argument that the PRE and spring are not located in the passageway in the accused  
25 devices; but this consideration is not relevant here, as the limitation in question makes no reference  
26 to such apparatus. As such, it appears the accused devices embody this limitation.

27 f. Infringement of the '674 Patent

1 As explained above, the accused devices embody Claim 1’s limitations with respect to the  
2 position of the PRE and the spring; the existence of a retainer device; the passage of fluid through  
3 the filter; and the removability of the filter through the exit opening. In addition to these, Claim 1  
4 also has numerous other limitations. Oceanic contends that the accused devices embody all of these  
5 remaining limitations, and Aqua-Lung has offered no argument to the contrary. Oceanic further  
6 alleges that the accused devices infringe Claims 2, 3, 6, 7, 8, 9, and 12, all of which are dependent  
7 on Claim 1. Oceanic has made a preliminary showing that each of these dependent claims is  
8 infringed, which Aqua-Lung has not contested.

9 Similarly, the accused devices embody Claim 13’s limitations with respect to the existence  
10 of a retainer device; the passage of fluid through the filter; the removability of the filter through the  
11 exit opening; and the existence of a “housing defining an internal passageway” which has gas inlets  
12 and outlets at opposing ends. Aqua-Lung does not appear to take issue with Oceanic’s argument  
13 that the accused devices embody the remaining limitations in Claim 13. Similarly, Oceanic alleges  
14 that the Titan and Legend devices infringe on Claims 14, 15, and 20-24, which depend on Claim 13.  
15 As with the dependent claims pertaining to Claim 1, Aqua-Lung has not contested these.

16 Thus, the undisputed facts indicate that the accused Titan and Legend devices infringe on the  
17 ’674 Patent. For this reason, Oceanic’s motion for summary judgment on infringement will be  
18 granted with respect to the ’674 Patent, and Aqua-Lung’s motion for summary judgment for a  
19 finding of non-infringement will be denied.<sup>3</sup>

20 2. The ’958 Patent

21 The ’958 Patent discusses a device called a “retractable valve member” (Claim 1) or a  
22 “retractable member” (Claim 8). The parties agree that this device does not differ materially from  
23 the PRE discussed in the ’674 Patent, and for convenience this discussion will continue to call it a  
24 PRE. See Aqua-Lung’s Memo in Support of Non-Infringement at 9; Oceanic’s Memo in Opposition  
25 to Non-Infringement at 3. The second limitation of Claim 1 and the second limitation of Claim 8

26 <sup>3</sup> As noted above, this holding applies only to the Titan and Legend lines. As to the Kronos line, the  
27 holding is reversed: summary judgment is granted in favor of Aqua-Lung and denied with respect  
28 to Oceanic.

1 describe the PRE, respectively, “within said passageway” and “within said duct.” ’958 Patent,  
2 col.18 l.7-8, 56. The Court construed “passageway” and “duct” identically, describing both terms as  
3 “a conduit formed in the housing that allows gas to pass through it.” Order Construing Claims at 9.

4 The parties’ arguments regarding these concepts resemble their arguments regarding the  
5 “bore” in the ’674 Patent, in that they disagree as to whether the PRE in the accused products can be  
6 said to be located within a “passageway” or “duct.” Aqua-Lung contends that its own design allows  
7 gas to flow through a conduit that is located on the interior of a fixed central post, and that there is  
8 no PRE located inside this conduit. Rather, Aqua-Lung avers, the PRE is located outside and  
9 surrounding the fixed central post where the gas flows. Oceanic counters that, in Aqua-Lung’s  
10 design, the PRE and the fixed central post where the gas flows are both located inside the same  
11 housing, and that the presence of the “non-integral center portion” does not detract from the fact that  
12 the PRE is within a duct or passageway where gas flows. In effect, Aqua-Lung’s position is that the  
13 “conduit” in question is the fixed central post, around which the PRE is wrapped; whereas Oceanic  
14 takes the position that the “conduit” in question is the larger housing that contains both the fixed  
15 central post and the PRE.

16 To determine who is correct, it is important to consider the plain meaning of “conduit.”  
17 According to the Court’s definition, the relevant “conduit” is one which is formed in the housing for  
18 the express purpose of guiding or directing the gas through the filter. Thus Aqua-Lung’s position—  
19 that the fixed central post is really the conduit in question—is more persuasive, because that post’s  
20 sole function is to direct gas flow. In contrast, the larger housing—to which Oceanic refers—  
21 encapsulates the PRE and the spring, as well as the smaller channel through which gas is directed;  
22 so it performs more functions than just directing gas. For this reason, it is more consistent with the  
23 Court’s claim construction order to interpret the claims in the ’958 Patent as protecting only PREs  
24 which are located within a conduit *whose sole purpose* is to direct gas flow through the filter. The  
25 PRE in Aqua-Lung’s design, by contrast, should not be considered to be positioned within a  
26 conduit, because the structure in which it is located houses not only the PRE, but also a spring and a  
27 smaller conduit that exists for the sole purpose of directing gas. For this reason, Aqua-Lung’s PRE  
28

1 cannot be said to be within a “duct” or “passageway.” As the accused products do not embody this  
2 limitation regarding PRE position, they cannot be said to infringe on Claims 1 and 8. Once again,  
3 determination of the issue does not turn on any disputed issues of fact.

4 Claims 1 and 8 are independent claims. Oceanic also asserts that Aqua-Lung has infringed  
5 Claim 7, which is dependent on Claim 1, and Claim 14, which is dependent on Claim 8. *See* ’958  
6 Patent, col. 18 l.43-45 & col.20 l.4-6. The Federal Circuit, however, has explained that “[o]ne may  
7 infringe an independent claim and not infringe a claim dependent on that claim. The reverse is not  
8 true. One who does not infringe an independent claim cannot infringe a claim dependent on (and  
9 thus containing all the limitations of) that claim.” *Monsanto Co. v. Syngenta Seeds, Inc.*, 503 F.3d  
10 1352, 1359 (Fed. Cir. 2007) (quoting *Wahpeton Canvas Co., Inc. v. Frontier, Inc.*, 870 F.2d 1546,  
11 1552 (Fed. Cir. 1989)). Accordingly, since Aqua-Lung has not infringed independent Claims 1 and  
12 8, it cannot be said to have infringed dependent Claims 7 and 14. As a result, Aqua-Lung’s motion  
13 for summary judgment for non-infringement will be granted in full with respect to the ’958 Patent.  
14 Correspondingly, Oceanic’s motion for summary judgment of infringement of this patent will be  
15 denied.

16 3. The ’609 Patent

17 The ’609 Patent refers to the PRE as a “retractable filter cover” (Claim 5), a “retractable  
18 member” (Claims 18 and 27), or “a gas flow control element” (Claim 37); but, as with the ’958  
19 Patent, the parties agree these are merely alternate names for the same device. Within the ’609  
20 Patent, the second limitation of Claim 5 and the second limitation of Claim 27 describe a PRE  
21 “within said passageway,” ’609 Patent, col. 20 l.16 & col.22 l.31-32, and the second limitation of  
22 Claim 18 and second limitation of claim 37 describe a PRE “within said duct,” *id.* col.21 l.21. As  
23 with the ’958 Patent, no issues of fact relevant to the question remain to be determined. The  
24 accused devices’ PREs simply cannot be said to exist within a passageway or duct as those terms are  
25 used in the ’609 Patent. Likewise, under *Monsanto*, Aqua-Lung cannot be said to have infringed  
26 Claims 29 and 30, both of which depend on Claim 27. Aqua-Lung’s motion for summary judgment  
27  
28

1 on its non-infringement claim will therefore be granted in full with respect to the '609 Patent.  
2 Similarly, Oceanic's motion for summary judgment of infringement of this patent will be denied.

3 B. Invalidity

4 Aqua-Lung's motion for summary judgment on the basis of invalidity is premised on its  
5 position that all claims of the three patents-in-suit fail to meet 35 U.S.C. § 112's written description  
6 requirement. The first paragraph of section 112 states: "The specification shall contain a written  
7 description of the invention, and of the manner and process of making and using it, in such full,  
8 clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with  
9 which it is most nearly connected, to make and use the same, and shall set forth the best mode  
10 contemplated by the inventor of carrying out his invention."

11 Each claim of a patent is presumed to be valid. 35 U.S.C. § 282; *Abbott Lab. v. Syntron*  
12 *Bioresearch, Inc.*, 224 F.3d 1343, 1357 (Fed. Cir. 2003). Patents may be held invalid for failure to  
13 meet the written description requirement of 35 U.S.C. § 112 when narrow specifications fail to  
14 support a broad claim. *Gentry Gallery, Inc. v. Berkline Corp.*, 134 F.3d 1473, 1479 (Fed. Cir.  
15 1998). Invalidity under § 112, however, is a question of fact. *Cordis Corp. v. Medtronic Ave., Inc.*,  
16 339 F.3d 1352, 1364. As previously noted, to obtain a finding of invalidity under § 112 prior to  
17 trial, a party "must submit such clear and convincing evidence of invalidity such that no reasonable  
18 jury could find otherwise." *Eli Lilly & Co. v. Barr Lab., Inc.*, 251 F.3d 955, 962 (Fed. Cir. 2001).

19 Here, Aqua-Lung contends that Oceanic's claims fail to meet the written description  
20 requirement because the alleged parent application of the patents-in-suit describes designs for fluid-  
21 activated valves only (of which Oceanic's gas-activated valves are one example).<sup>4</sup> Therefore, Aqua-  
22 Lung contends that, under the written description doctrine, the claim language cannot validly reach

23 <sup>4</sup> The claimed parent application for all three of the patents-in-suit was filed on June 1, 2001. U.S.  
24 Patent Application No. 09/872,130 (the "'130 Application"). These drawings, as well as the portion  
25 of the specification pertaining to mechanically-operated valves, were added via a now-abandoned  
26 continuation-in-part ("CIP"), filed February 28, 2002, from which the '674 Patent's application is  
27 derived. It is not presently clear whether Oceanic may claim priority for the amended material back  
28 to the '130 Application's original priority date in June 2001, or if the proper priority date is the  
February 2002 date when the amendments were filed. These differing priority dates, however, are  
not material to the present discussion. Regardless of which priority date Oceanic is entitled to, the  
sufficiency of the written description turns on what exists in the patent's specification as issued, and  
not on what may have existed in an original application.

1 valves operating in *other* ways. For example, valves could be mechanically-operated, like Aqua-  
2 Lung’s. Aqua-Lung further suggests they could be manually operated, temperature responsive,  
3 electrical, or operated by magnets. At any rate, the basic argument is that the claims of the patents-  
4 in-suit cannot be validly read to extend to non-fluid-operated valves like those embodied in the  
5 accused products.

6 Oceanic complains that this argument is an improper attempt import limitations from the  
7 specifications into the claims. It is axiomatic that “a court may not read a limitation into a claim  
8 from the specification.” *Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc.*, 381 F.3d  
9 1111, 1117 (Fed. Cir. 2004); *White v. Dunbar*, 119 U.S. 47, 52 (1886) (“The context may,  
10 undoubtedly, be resorted to, and often is resorted to, for the purpose of better understanding the  
11 meaning of the claim; but not for the purpose of changing it, and making it different from what it  
12 is.”). In the landmark *Gentry Gallery* case, the Federal Circuit noted that “a claim may be broader  
13 than the specific embodiment disclosed in a specification,” and that “[a]n applicant is entitled to  
14 claims as broad as the prior art and his disclosure will allow.” 134 F.3d at 1480. Nonetheless, no  
15 “applicant can broaden his claims to the extent that they are effectively bounded only by the prior  
16 art.” *Id.* Rather, “claims may be no broader than the supporting disclosure, and therefore . . . a  
17 narrow disclosure will limit claim breadth.” *Id.* “*Gentry Gallery*, then, considers the situation  
18 where the patent’s disclosure makes crystal clear that a particular (i.e., narrow) understanding of a  
19 claim term is an ‘essential element of [the inventor’s] invention.’” *Johnson Worldwide Assocs., Inc.*  
20 *v. Zebco Corp.*, 175 F.3d 985, 993 (Fed. Cir. 1999). *Gentry Gallery* does not, however, mandate an  
21 inquiry into what an inventor considers to be essential to his invention, nor does it require that the  
22 claims incorporate those limitations. *Cooper Cameron Corp. v. Kvaerner Oilfield Prods., Inc.*, 291  
23 F.3d 1317, 1323 (Fed. Cir. 2002).

24 In this case, Aqua-Lung’s argument is unpersuasive with respect to the ’609 and ’958  
25 Patents. The abstracts of these two patents, which summarize their respective specifications,  
26 disclose a PRE “disposed within the passageway for selectively opening and closing the inlet  
27 opening to fluid flow in response to *fluid pressure* exerted thereon at the inlet opening” (emphasis  
28

1 added). Similarly, the claims of these two patents discuss a PRE that is located within the  
2 passageway *through which fluid is flowing*. *E.g.*, '609 Patent, col. 20 1.16 & col.22 1.31-32; '958  
3 Patent, col.18 1.7-8, 56. This apparently close match between the specifications and the claims  
4 reflects the flaw in Aqua-Lung's contention that, as a matter of law, the written description  
5 requirement is not satisfied here. Indeed, as explained above, Aqua-Lung's accused products do  
6 not infringe on these patents precisely because their PREs, which are not gas-pressure activated, are  
7 located outside the passageway through which the gas flows. Aqua-Lung is therefore not entitled to  
8 summary judgment on its invalidity claim with respect to the '609 and '958 Patents.

9 The analysis is somewhat different with respect to the '674 Patent. The claim language (as  
10 construed above) and the specification language are both broader here. The patent's abstract omits  
11 the key term "fluid" which is employed in the earlier patents' abstracts: it discloses a PRE  
12 "disposed within the passageway for selectively opening and closing the inlet opening to fluid flow  
13 in response to *pressure* exerted thereon at the inlet opening" (emphasis added). Likewise, the  
14 specification itself, after explaining the operation of a fluid-activated mechanism, states: "An  
15 alternative fail-safe mechanism for operating the inlet valve of the present invention involves  
16 *mechanical pressure* in the form of physical contact against the pressure responsive element in lieu  
17 of fluid pressure." '674 Patent, col. 19, 1.5-7; *see also id.*, figs. 43-60 (illustrating the operation of  
18 mechanically operated valves).

19 Similarly, the claim language describes a PRE and spring assembly operating within a bore  
20 but does not in any way limit that PRE's activation to fluid flow. As explained in detail above, a  
21 bore may house elements in addition to a conduit for fluid flow. Thus the PRE's location within the  
22 bore, standing alone, does not indicate one way or another how it is activated. Rather, the claim  
23 language, like the specification language, leaves plenty of room for both mechanically activated and  
24 fluid pressure activated PREs. For this reason, there is enough of a match between the  
25 specifications and the claims to indicate that Aqua-Lung cannot meet its summary judgment burden  
26 of showing, as a matter of law, the inadequacy of the written description. Consequently, Aqua-

27  
28

1 Lung’s motion for summary judgment on invalidity must be denied with respect to the ’674 Patent  
2 as well.

3 C. Fraud

4 Next, Aqua-Lung seeks summary judgment on Oceanic’s counterclaim for fraud. “A cause  
5 of action for fraud [under California law] requires the plaintiff to prove (a) a knowingly false  
6 misrepresentation by the defendant, (b) made with the intent to deceive or to induce reliance by the  
7 plaintiff, (c) justifiable reliance by the plaintiff, and (d) resulting damages.” *Glenn K. Jackson Inc. v.*  
8 *Roe*, 273 F.3d 1192 (9th Cir. 2001) (quoting *Wilkins v. Nat’l Broadcasting Co., Inc.*, 71 Cal.App.4th  
9 1066, 1082 (1999)); *see also* Cal. Civil Code § 1572.

10 Here, the essence of Oceanic’s fraud counterclaim is its contention that Aqua-Lung kept  
11 egging on TFD during negotiations over licensing TFD’s valve technology, thereby inducing TFD  
12 to disclose more and more information. All along, according to Oceanic, Aqua-Lung had no  
13 intention of entering into a license agreement. The counterclaim, however, lacks specificity on this  
14 point. It merely states: “Aqua-Lung conveyed [the] fact that it was interested in licensing the  
15 technology, which Aqua-Lung knew to be false.” Answer and Counterclaim, ¶ 51. Oceanic has not  
16 pointed to a particular statement by Aqua-Lung that it contends was false. Rather it offers only the  
17 general averment that Aqua-Lung employees led on TFD. To establish fraud, however, at least a  
18 preliminary showing that an Aqua-Lung employee made a particular statement, knowing it to be  
19 false even when made, would be required. *See* Cal. Civil Code § 1572(1) (defining actual fraud as  
20 “[t]he suggestion, as a fact, of that which is not true, by one who does not believe it to be true”).

21 Based on these principles, even drawing all reasonable inferences in favor of Oceanic, no  
22 genuine issues of material fact exist which would allow Oceanic’s fraud counterclaim to proceed.  
23 Aqua-Lung’s motion for summary judgment on this counterclaim therefore must be granted.

24 D. Trade Secret Misappropriation

25 Aqua-Lung also seeks summary judgment on TFD’s counterclaim for trade secret  
26 misappropriation. This claim is based on Cal. Civil Code § 3426.1, which prohibits “disclosure or  
27 use of a trade secret of another without express or implied consent by a person who . . . (B) at the  
28

1 time of disclosure or use, knew or had reason to know that his or her knowledge of the trade secret  
2 was: . . . (ii) acquired under circumstances giving rise to a duty to maintain its secrecy or limit its  
3 use.” The statute defines a trade secret as information that “(1) Derives independent economic  
4 value, actual or potential, from not being generally known to the public or to other persons who can  
5 obtain economic value from its disclosure or use; and (2) Is the subject of efforts that are reasonable  
6 under the circumstances to maintain its secrecy.” Cal. Civil Code § 3426.1(d). “When information  
7 has no independent economic value, a claim for misappropriation lacks merit.” *Gemini Aluminum*  
8 *Corp. v. Calif. Custom Shapes, Inc.*, 95 Cal. App. 4th 1249, 1262 (Cal. App. 2002) (citation  
9 omitted).

10 Oceanic served Aqua-Lung with an initial identification of trade secrets, in accordance with  
11 California statutory law. *See* Cal. Civ. Proc. Code § 2019.210 (“In any action alleging the  
12 misappropriation of a trade secret under the Uniform Trade Secrets Act . . . , before commencing  
13 discovery relating to the trade secret, the party alleging the misappropriation shall identify the trade  
14 secret with reasonable particularity[.]”). This disclosure asserted that TFD had disclosed “a fluid  
15 flow control valve” embodied in “a number of prototypes [which] contained structure for preventing  
16 moisture intrusion and contamination of regulators.” TFD’s Identification of Trade Secrets,  
17 attached as Exh. 1 to Aqua-Lung’s Motion for Summary Judgment as to Trade Secret  
18 Misappropriation, at 2-3. Language elaborating on the nature of the “fluid flow control valve”  
19 appeared to be drawn almost verbatim from the patent claims. *Id.* at 1 (describing the valve as  
20 “having a housing defining an inlet and an outlet, and including a pressure responsive element for  
21 selectively opening and closing the inlet opening to fluid flow in response to a force exerted on the  
22 pressure responsive element, with a mechanism for exerting a bias force against the pressure  
23 responsive element sufficient to close the inlet opening to fluid flow absent a pre-established force  
24 exerted on the pressure responsive element in opposition to the bias force”).

25 This information was supplemented by Aqua-Lung’s deposition of Shane Taylor, the  
26 inventor of the technology at issue in this suit. He stated that the trade secret he believes Aqua-  
27 Lung misappropriated was “dry valve technology.” Taylor Depo., attached as Exh. 5 to Aqua-  
28

1 Lung’s Motion for Summary Judgment as to Trade Secret Misappropriation, at 260, 1.1-2. When  
2 asked to clarify, he defined “dry valve technology” as “the technology . . . for regulators, preventing  
3 the water from getting in the regulator, first stage” and “*the technology of the fluid flow control*  
4 *valve in my first [patent] application and from that point forward.*” *Id.* 1.12-15; 261, 1.14-16  
5 (emphasis added). The following exchange then ensued:

6 Q: That is what you mean by dry valve technology?

7 A: That is what I mean by dry valve technology, everything I just listed. And it is  
8 definitely not limited to what I just listed. . . . I have defined it verbally the best way  
9 I can. At this time, that is my answer for you.

10 Q: You can’t be any more precise?

11 A: No. I can’t be any more precise at this time.

12 *Id.* at 1.17-22; 262 1.5-10.

13 In short, the initial identification of trade secrets and the inventor’s deposition do not reveal  
14 that the allegedly misappropriated technology was anything other than what was described in the  
15 patents-in-suit. It is a long-held tenet of patent law that issuance of a patent extinguishes any action  
16 for protection of the technology covered by such patent as a trade secret. *E.g., Newport Indus. v.*  
17 *Crosby Naval Stores*, 139 F.2d 611 (5th Cir. 1944) (“A trade secret . . . cannot possibly be patented.  
18 This claim is a separate one, just as a suit for appropriation of literary property is separate from a  
19 suit under the copyright laws.”). A patent is a public record, the issuance of which results in a  
20 public disclosure of the claims and specifications of the patent in return for a limited patent  
21 monopoly. Therefore, a plaintiff has a viable trade secret claim that would protect his proprietary  
22 unpatented technology, only if he reveals “implementation details and techniques” *beyond* what was  
23 disclosed in his patent. *See Celeritas Techs., Ltd. v. Rockwell Int’l Corp.*, 150 F.3d 1354, 1358  
24 (Fed. Cir. 1998).

25 Here, Taylor’s initial patent application was filed on June 1, 2001 and published on  
26 December 5, 2002. It is undisputed that no disclosures took place before June 15, 2002. TFD  
27 Responses to Request for Admission, attached as Exh. 11 to Aqua-Lung’s Motion for Summary  
28

1 Judgment as to Trade Secret Misappropriation, ¶ 17. Thus, the period of time from June 15, 2002,  
2 to December 5, 2002 was the only time during which Aqua-Lung could conceivably have  
3 misappropriated a trade secret—that is, information that was not already public knowledge.

4 It is also undisputed that Aqua-Lung did not commence selling regulators containing an  
5 automatic closure device until early 2006, more than three years after the publication of the patent  
6 application and three and a half years after Aqua-Lung’s June 15, 2002, meeting with Taylor. The  
7 regulators sold at this time by Aqua-Lung were the subject of a separate patent, U.S. Patent No.  
8 7,334,772 (the “’772 Patent”), which was issued to a subsidiary of Aqua-Lung itself. Crucially, the  
9 ’772 Patent cites all three of the patents-in-suit as prior art; and the USPTO will not issue a patent if  
10 the proposed invention is “anticipated by any prior invention or device” or “obvious through  
11 application of any prior art.” 35 U.S.C. §§ 102, 103.

12 This would suggest that, even if Aqua-Lung gleaned trade secrets from its meetings with  
13 Taylor during the narrow window of time between June and December 2002, Aqua-Lung in fact did  
14 not disclose or use such information. The plain language of § 3426.1 prohibits only the disclosure  
15 or use of a trade secret, not its mere possession. *See AccuImage Diagnostics Corp v. Terarecon,*  
16 *Inc.*, 260 F. Supp. 2d 941, 951 n.5 (N.D. Cal. 2003). Oceanic, however, offers expert testimony  
17 suggesting that Aqua-Lung introduced products incorporating the technology described in the ’772  
18 Patent approximately six months earlier than it otherwise could have, had it not been for early  
19 access to Taylor’s technology. Aqua-Lung counters that three years elapsed between its meetings  
20 with Taylor and the issuance of the ’772 Patent, and this proves that Aqua-Lung did not gain any  
21 unfair advantage through alleged use of Taylor’s designs.

22 These two competing positions suggest the existence of unresolved issues of fact  
23 surrounding the trade secret misappropriation dispute. Disclosure and/or use of the trade secret in  
24 question is a crucial element of a misappropriation claim, and Oceanic has made a sufficient  
25 showing that genuine issues of material fact exist on this element. Furthermore, it has also made a  
26 preliminary showing of fact as to the other elements of trade secret misappropriation. As genuine  
27  
28

1 issues of material fact exist on this claim, Aqua-Lung's motion for summary judgment must be  
2 denied.

3 V. CONCLUSION

4 For the reasons stated above, (1) Aqua-Lung's motion for summary judgment on its non-  
5 infringement claim is granted as to the '958 Patent and the '609 Patent, and Oceanic's cross-motion  
6 for summary judgment on its infringement claim is likewise denied as to these two patents; (2)  
7 Oceanic's motion for summary judgment on its infringement claim relating to the '674 Patent is  
8 granted and Aqua-Lung's corresponding motion for summary judgment on its non-infringement  
9 claim is denied; (3) Aqua-Lung's motion for summary judgment on Oceanic's fraud counter-claim  
10 is granted; (4) Aqua-Lung's motion for summary judgment on its invalidity claim is denied; and (5)  
11 Aqua-Lung's motion for summary judgment on Oceanic's trade secret misappropriation counter-  
12 claim is denied.

13 The parties shall appear for a supplemental case management conference on **June 10, 2010,**  
14 **at 10:00 a.m.** in Courtroom 3, 17th Floor, United States Courthouse, 450 Golden Gate Avenue, San  
15 Francisco, California. A supplemental joint case management statement should be filed no later  
16 than **June 3, 2010.**

17  
18 IT IS SO ORDERED.

19  
20 Dated: 04/28/2010

21   
22 RICHARD SEEBORG  
23 UNITED STATES DISTRICT JUDGE  
24  
25  
26  
27  
28